ArticleThe oncologist2026
PD-1 inhibitor treatment outcomes for cutaneous squamous cell carcinoma in patients over 85: a comparative analysis.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgrammed-cell death protein 1 (PD-1) inhibitors have become standard of care in the treatment of advanced or metastatic cutaneous squamous cell carcinoma (cSCC). However, insufficient data exists regarding treatment outcomes and safety among elderly patients, including patients aged >85. PATIENTS AND
methodsWe retrospectively reviewed patients aged >85 (n = 52) and compared them with two control groups: 46 patients aged 71-84 and 32 patients <70, treated with cemiplimab for cSCC. Demographics, treatment characteristics, outcomes and toxicity were evaluated. Inverse probability of treatment weighting (IPTW) was applied when comparing survival outcomes.
resultsAlthough patients >85 had worse ECOG scores and less inclined to undergo surgery, no significant differences were noted in the overall response rates (68.8% and 76.1% for <70 and 71-84, respectively vs. 73.1% for >85, P = .744) or disease control rates (75% and 82.6% for <70 and 71-84, respectively vs. 75% for >85, P = .627). After IPTW adjustment, progression-free survival (PFS) did not differ between groups (HR = 1.08, 95% CI 0.55-2.13, P = .82). Cancer specific survival (CSS) also did not differ between groups (HR = 1.05, 95% CI 0.22-4.87, P = .955). However, overall survival (OS) was shorter among patients >85 (HR = 2.64, 95% CI 1.43-4.86, P = .002). Toxicity profiles were similar, although toxicity-related deaths occurred more frequently in the >85 cohort.
conclusionCemiplimab showed comparable efficacy and tolerability across age groups, with no significant difference in PFS and CSS, but shorter OS among very elderly patients with cSCC, reflecting competing non-cancer mortality rather than reduced treatment efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.